Sarepta Therapeutics (SRPT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$22.50-2.13%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SRPT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 1,974.3 | 2,198.2 | 1,902.0 | 1,243.3 | 933.0 | 701.9 | 540.1 | 380.8 | 301.0 | 154.6 | 5.4 | — | — | — | — | — |
| Total Revenues | 1,974.3 | 2,198.2 | 1,902.0 | 1,243.3 | 933.0 | 701.9 | 540.1 | 380.8 | 301.0 | 154.6 | 5.4 | — | — | — | — | — |
| Cost of Revenues | — | 25.5 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 436.7 | 491.7 | 557.9 | 481.9 | 451.4 | 282.7 | 317.9 | 284.8 | 207.8 | 122.7 | 83.7 | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — | — | — | — | 401.8 | 166.7 | 188.3 | 146.4 | 94.2 | 72.9 | 52.4 | 66.9 |
| Operating Income | (143.2) | (699.8) | 218.1 | (267.8) | (536.2) | (459.7) | (564.2) | (705.6) | (343.6) | (171.6) | (266.7) | (220.2) | (133.8) | (90.3) | (29.7) | (35.9) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | (66.0) | (38.1) | (18.4) | (22.0) | (53.2) | 63.5 | 59.9 | 30.7 | 33.7 | 5.8 | — | — | — | — | — | — |
| Interest & Investment Income | 27.9 | 30.8 | 30.6 | 36.3 | 16.5 | 0.4 | 3.0 | 7.2 | 6.8 | 1.8 | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | (58.3) | (69.7) | 63.2 | 57.0 | 23.4 | 26.9 | 4.0 | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | 12.3 | (2.4) | 42.7 | (252.3) | (153.8) | 40.8 | 11.1 | (8.3) | (19.0) | 123.0 | (0.5) | 0.2 | (2.0) | (21.7) | (91.6) | 33.6 |
| EBT, Incl. Unusual Items | (130.9) | (702.2) | 260.8 | (520.1) | (690.0) | (418.9) | (553.1) | (713.9) | (362.6) | (48.6) | — | — | — | — | — | — |
| Income Tax Expense | 5.8 | 11.2 | 25.5 | 15.9 | 13.5 | (0.2) | 1.1 | 1.2 | (0.7) | 2.1 | — | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | (266.1) | (713.4) | 235.2 | (536.0) | (703.5) | (418.8) | (554.1) | (715.1) | (361.9) | (50.7) | (267.3) | (220.0) | (135.8) | (112.0) | (121.3) | (2.3) |
| Per Share | ||||||||||||||||
| Basic EPS | (2.52) | (7.13) | 2.47 | (5.80) | (8.03) | (5.15) | (7.11) | — | — | — | — | — | — | — | — | (0.02) |
| Diluted EPS | (2.52) | (7.13) | 2.34 | (5.80) | (8.03) | (5.15) | (7.11) | — | — | — | — | — | — | — | — | (0.02) |
| Revenue per Share | 18.73 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 105.4 | 100.1 | 95.1 | 92.4 | 87.6 | 81.3 | 78.0 | 73.6 | 66.3 | 58.8 | 48.7 | 42.3 | 40.0 | 33.9 | 23.6 | 21.6 |
| Diluted Weighted Avg Shares | 105.4 | 100.1 | 107.9 | 92.4 | 87.6 | 81.3 | 78.0 | 73.6 | — | — | — | — | — | — | — | 129.6 |
| Supplemental | ||||||||||||||||
| EBITDA | — | (655.3) | 255.8 | (223.4) | (494.3) | (421.7) | (537.3) | (681.1) | (331.4) | (163.5) | (261.1) | (214.9) | (130.1) | (89.0) | (28.2) | (34.6) |
| EBIT | (143.2) | (699.8) | 218.1 | (267.8) | (536.2) | (459.7) | (564.2) | (705.6) | (343.6) | (171.6) | (266.7) | (220.2) | (133.8) | (90.3) | (29.7) | (35.9) |
| Effective Tax Rate | -4.4% | — | — | -3.1% | -2.0% | 0.0% | -0.2% | -0.2% | 0.2% | -4.2% | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.